메뉴 건너뛰기




Volumn 34, Issue 1, 2016, Pages 88-93

A randomised trial evaluating anakinra in early active rheumatoid arthritis

Author keywords

Clinical trial; Interleukin 1 receptor antagonist protein; Rheumatoid arthritis

Indexed keywords

METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ANTIRHEUMATIC AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

EID: 84958794088     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (34)

References (15)
  • 1
    • 84958822343 scopus 로고    scopus 로고
    • National Institute for Health and Care Excellence: Rheumatoid arthritis: the management of rheumatoid arthritis in adults. NICE guidelines [CG79] NICE Website, [cited 2015 11th February]. Available from
    • National Institute for Health and Care Excellence: Rheumatoid arthritis: the management of rheumatoid arthritis in adults. NICE guidelines [CG79] NICE Website 2009 [cited 2015 11th February]. Available from: http://www.nice.org.uk/TA130.
    • (2009)
  • 3
    • 84958770453 scopus 로고    scopus 로고
    • Anakinra Product Approval Information -Licensing Action 2001
    • cited, 19th December, Available from
    • US Food and Drug Administration (FDA):Anakinra Product Approval Information -Licensing Action 2001 [cited 2013 19th December]. Available from: http://www.fda. gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080650.htm.
    • (2013)
  • 4
    • 67149130597 scopus 로고    scopus 로고
    • Anakinra for rheumatoid arthritis: a systematic review
    • MERTENS M, SINGH JA: Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol 2009; 36: 1118-25.
    • (2009) J Rheumatol , vol.36 , pp. 1118-1125
    • Mertens, M.1    Singh, J.A.2
  • 5
    • 84868454136 scopus 로고    scopus 로고
    • Timing the therapeutic window of opportunity in early rheumatoid arthritis: proposal for definitions of disease duration in clinical trials
    • RAZA K, SABER TP, KVIEN TK, TAK PP, GERLAG DM: Timing the therapeutic window of opportunity in early rheumatoid arthritis: proposal for definitions of disease duration in clinical trials. Ann Rheum Dis 2012; 71: 1921-3.
    • (2012) Ann Rheum Dis , vol.71 , pp. 1921-1923
    • Raza, K.1    Saber, T.P.2    Kvien, T.K.3    Tak, P.P.4    Gerlag, D.M.5
  • 6
    • 0037103342 scopus 로고    scopus 로고
    • Long-term outcome in rheumatoid arthritis: a simple algorithm of baseline parameters can predict radiographic damage, disability, and disease course at 12-year followup
    • DROSSAERS-BAKKER KW, ZWINDERMAN AH, VLIET VLIELAND TP et al.: Long-term outcome in rheumatoid arthritis: a simple algorithm of baseline parameters can predict radiographic damage, disability, and disease course at 12-year followup. Arthritis Rheum 2002; 47: 383-90.
    • (2002) Arthritis Rheum , vol.47 , pp. 383-390
    • Drossaers-Bakker, K.W.1    Zwinderman, A.H.2    Vliet Vlieland, T.P.3
  • 7
    • 84903536740 scopus 로고    scopus 로고
    • Radiological outcomes in randomized controlled trials on biologic therapies for rheumatoid arthritis: a narrative review.
    • BIZZI E, MASSAFRA U, LAGANA B et al.:Radiological outcomes in randomized controlled trials on biologic therapies for rheumatoid arthritis: a narrative review. Clin Rheumatol 2014; 33: 877-84.
    • (2014) Clin Rheumatol , vol.33 , pp. 877-884
    • Bizzi, E.1    Massafra, U.2    Lagana, B.3
  • 9
    • 0026684213 scopus 로고
    • Determination of cytokines in synovial fluids: correlation with diagnosis and histomorphological characteristics of synovial tissue
    • KAHLE P, SAAL JG, SCHAUDT K, ZACHER J, FRITZ P, PAWELEC G: Determination of cytokines in synovial fluids: correlation with diagnosis and histomorphological characteristics of synovial tissue. Ann Rheum Dis 1992; 51: 731-4.
    • (1992) Ann Rheum Dis , vol.51 , pp. 731-734
    • Kahle, P.1    Saal, J.G.2    Schaudt, K.3    Zacher, J.4    Fritz, P.5    Pawelec, G.6
  • 10
    • 0032752705 scopus 로고    scopus 로고
    • IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen- induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation
    • JOOSTEN LA, HELSEN MM, SAXNE T, van De LOO FA, HEINEGARD D, van Den BERG WB: IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen- induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. J Immunol 1999; 163: 5049-55.
    • (1999) J Immunol , vol.163 , pp. 5049-5055
    • Joosten, L.A.1    Helsen, M.M.2    Saxne, T.3    Van De Loo, F.A.4    Heinegard, D.5    Van Den Berg, W.B.6
  • 11
    • 0034083128 scopus 로고    scopus 로고
    • A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores
    • JIANG Y, GENANT HK, WATT I et al.: A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 2000; 43:1001-9.
    • (2000) Arthritis Rheum , vol.43 , pp. 1001-1009
    • Jiang, Y.1    Genant, H.K.2    Watt, I.3
  • 12
    • 84931571929 scopus 로고    scopus 로고
    • Anakinra treatment in drug-resistant Behcet's disease: a case series.
    • CANTARINI L, VITALE A, SCALINI P et al.:Anakinra treatment in drug-resistant Behcet's disease: a case series. Clin Rheumatol 2015; 34: 1293-301.
    • (2015) Clin Rheumatol , vol.34 , pp. 1293-1301
    • Cantarini, L.1    Vitale, A.2    Scalini, P.3
  • 13
    • 84875963811 scopus 로고    scopus 로고
    • Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review.
    • Ter HAAR N, LACHMANN H, OZEN S et al.:Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis 2013; 72: 678-85.
    • (2013) Ann Rheum Dis , vol.72 , pp. 678-685
    • Ter Haar, N.1    Lachmann, H.2    Ozen, S.3
  • 14
    • 84958822344 scopus 로고    scopus 로고
    • ClinicalTrials.gov: Anakinra for Behçets Disease, [cited 2015 13th July]. Available from
    • ClinicalTrials.gov: Anakinra for Behçets Disease 2011 [cited 2015 13th July]. Available from: https://clinicaltrials.gov/show/NCT01441076.
    • (2011)
  • 15
    • 0036222477 scopus 로고    scopus 로고
    • Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the Sharp/van der Heijde and Larsen/Scott scoring methods by clinical experts and comparison with the smallest detectable difference
    • BRUYNESTEYN K, van der HEIJDE D, BOERS M et al.: Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the Sharp/van der Heijde and Larsen/Scott scoring methods by clinical experts and comparison with the smallest detectable difference. Arthritis Rheum 2002; 46: 913-20.
    • (2002) Arthritis Rheum , vol.46 , pp. 913-920
    • Bruynesteyn, K.1    Van Der Heijde, D.2    Boers, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.